Optimizing clinical outcomes for bronchoscopic lung volume reduction with Zephyr® valves

T. David Koster, Pallav L. Shah, Arschang Valipour, Gerard J. Criner, Felix J.F. Herth, Richard Sue, Douglas K. Hogarth, Ralitza T. Martin, Amit K. Mahajan, Raed Alalawi, Lisa Kopas, Avi Cohen, Douglas E. Wood, Jonathan Kurman, Narinder S. Shargill, Mark Dransfield, Dirk Jan Slebos, Michael Perch

Research output: Contribution to journalReview articlepeer-review


Bronchoscopic lung volume reduction treatment with Zephyr one-way valves is an effective guideline-based treatment option for patients with severe emphysema and hyperinflation. However, in some cases the treatment response is less than anticipated or there might be a loss of initial treatment effect. Reasons for the lack of response can include incorrect assessment of collateral ventilation, improper valve placement, or patient related factors. Loss of initial benefit can be due to granulation tissue formation and subsequent valve dysfunction, or there may be side effects such as excessive coughing or infectious problems. Careful follow-up after treatment with valves is important and evaluation with a CT scan and/or bronchoscopy is helpful if there is no improvement after treatment or loss of initial benefit. This paper aims to describe the most important causes and provide a strategy of how to approach and manage these patients.

Original languageEnglish (US)
Article number107639
Pages (from-to)107639
JournalRespiratory Medicine
Early online dateApr 18 2024
StatePublished - Jun 2024


  • Bronchoscopic lung volume reduction
  • Bronchoscopy
  • COPD
  • Endobronchial valves
  • Granulation tissue
  • Pneumothorax

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Optimizing clinical outcomes for bronchoscopic lung volume reduction with Zephyr® valves'. Together they form a unique fingerprint.

Cite this